Topic: Reference-Scaled Approaches for Highly Variable Drugs

Handling Missing Periods in Reference-Scaled Analyses

FDA and EMA Reference-Scaling Decisions Compared

Estimating Reference Variability in Full Replicate Designs

Estimating Reference Variability in Partial Replicate Designs

Explaining Discordant FDA and EMA Results

Deriving the Log-Scale Expansion of Equivalence Limits

Constructing the FDA Upper Confidence Bound

Converting Between Log-Scale SD and Within-Subject CV

Degrees of Freedom for Scaled Variance Estimates

Choosing Endpoints for Reference-Scaled Analysis